LEONIDaS Caregivers Study (LEONIDaS)

The LEONIDaS(Long Term Exploration of Outcomes From New Interventions in Dravet Syndrome) Caregivers Study

Dravet syndrome is a rare form of severe epilepsy that begins in the first year of life and is associated with frequent and/or prolonged seizures. Individuals with Dravet Syndrome often experience a range of comorbidities, including behavioral and developmental delays, movement and balance issues, sleep difficulties, chronic infections, and growth and nutritional issues. Patients with Dravet syndrome are at high risk of death due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents, and infections.

Due to the severity of this condition, parents of children with Dravet syndrome are typically highly involved in their child's 24-hour care and this has a considerable impact on family life. Recent studies have highlighted the profound impact that such caregiving has on physical health, mental health, social function and financial resources. In particular, caregivers report high levels of stress and anxiety, fatigue, depression and social isolation. However, there is currently a lack of effective interventions to reduce the negative impact of caregiving on caregivers.

The aim of this study is to prospectively study carers of individuals with Dravet syndrome to identify pharmacological and psychological factors that are associated with increased or decreased vulnerability to stress, depression and anxiety. Using a naturalistic, observational design the investigators will assess a cohort of Dravet Syndrome carers every six months for 3 years in order to further characterise trajectories of caregiver burden and the factors that influence this, including factors related to the person with Dravet syndrome (e.g. age, seizure frequency/severity, treatment/medications, comorbidities) and factors related to the carer and family environment (e.g. social engagement/isolation, fatigue, finances, relationships). The investigators will use both standardized questionnaires and a neurocognitive task (Facial Expression Recognition Task) to assess vulnerability to anxiety and depression. The study will be conducted online.

Study Overview

• Status: Withdrawn
• Conditions: Depression; Anxiety; Dravet Syndrome
• Intervention / Treatment: Drug: Multiple; Other: Multiple

• Study Type: Observational

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Caregivers of individuals with Dravet syndrome

Description

Inclusion Criteria:

• Willing and able to give informed consent for participation in the study
• Aged 18 years or above
• Primary caregiver of an individual with a medical history supporting a clinical diagnosis of Dravet syndrome
• Able to access the internet

Exclusion Criteria:

• Inability to provide informed written consent
• Another caregiver of the same individual with Dravet is already enrolled in the study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Primary caregivers of individuals with Dravet Syndrome	Drug: Multiple; We will collect information on all medications taken by the caregiver and the person they care for.; Other: Multiple; We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anxiety and depression scores on the Hospital Anxiety and Depression Scale (HADS)	Higher scores indicate higher symptom levels (worse outcome)	Follow up at three years
Anxiety and depression scores on the Hospital Anxiety and Depression Scale (HADS)	Higher scores indicate higher symptom levels (worse outcome)	Follow up at two years
Anxiety and depression scores on the Hospital Anxiety and Depression Scale (HADS)	Higher scores indicate higher symptom levels (worse outcome)	Follow up at one year
Caregiver stress scores on the UW Caregiver Stress Scale	Higher scores indicate higher symptom levels (worse outcome)	Follow up at three years
Caregiver stress scores on the UW Caregiver Stress Scale	Higher scores indicate higher symptom levels (worse outcome)	Follow up at two years
Caregiver stress scores on the UW Caregiver Stress Scale	Higher scores indicate higher symptom levels (worse outcome)	Follow up at one year
Emotional processing biases on the Facial Expression Recognition Task (FERT)		Follow up at three years
Emotional processing biases on the Facial Expression Recognition Task (FERT)		Follow up at two years
Emotional processing biases on the Facial Expression Recognition Task (FERT)		Follow up at one year

Collaborators and Investigators

• Sponsor: University of Oxford
• Collaborators: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• Investigators: Principal Investigator: Catherine Harmer, PhD, University of Oxford

Study record dates

Study Major Dates

• Study Start (Estimated): October 26, 2023
• Primary Completion (Actual): October 26, 2023
• Study Completion (Actual): October 26, 2023

Study Registration Dates

• First Submitted: October 22, 2021
• First Submitted That Met QC Criteria: November 17, 2021
• First Posted (Actual): December 1, 2021

Study Record Updates

• Last Update Posted (Estimated): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 7, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy, Generalized; Epileptic Syndromes; Disease; Epilepsy; Epilepsies, Myoclonic; Syndrome
• Other Study ID Numbers: R76178/RE001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No